Clinical Trials Logo

Lung Neoplasms clinical trials

View clinical trials related to Lung Neoplasms.

Filter by:

NCT ID: NCT04487093 Recruiting - Clinical trials for Non Small Cell Lung Cancer

Clinical Study of Neoantigen Vaccine Combined With Targeted Drugs in the Treatment of Non-small Cell Lung Cancer

Start date: May 17, 2020
Phase: Phase 1
Study type: Interventional

Neoantigen vaccine is a new field of research in tumor immunotherapy, and some studies have been conducted with success on Melanoma and glioblastoma. Nearly 80% of lung cancers are diagnosed in an advanced stage (IIIB, and IV) and EGFR mutant non-small cell lung cancer will be resistant after targeted drug treatment. Neoantigen vaccine is a new treatment method for lung cancer, especially for patients with drug resistance.

NCT ID: NCT04471727 Recruiting - Clinical trials for Small-Cell Lung Cancer

Study in Patients With Advanced Cancers Associated With Expression of DLL3

Start date: December 29, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN328 Monotherapy and HPN328 With Atezolizumab in Patients With Advanced Cancers Associated With Expression of Delta-like Canonical Notch Ligand 3 (DLL3)

NCT ID: NCT04462185 Recruiting - Pulmonary Nodules Clinical Trials

A Prospective Cohort Study of Chinese Patients With Pulmonary Nodules: Prediction of Lung Cancer Using Noninvasive Biomarkers

Start date: July 1, 2020
Phase:
Study type: Observational

The broad goals of this study is to identify changes in genomic landscape during transition from stage 0 to stage 1 lung cancer. This study intends to determine whether diagnostic biomarkers measured in minimally invasive biospecimens are able to correlate molecular, clinical and imaging features to distinguish malignant from benign pulmonary nodules. The diagnostic markers once validated can be used as broad screening tools for lung cancer.

NCT ID: NCT04459065 Recruiting - Lung Cancer Clinical Trials

Evaluation of IRDye800CW-nimotuzumab in Lung Cancer Surgery

Start date: September 1, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the safety, optimal dose and imaging time of the investigational product, IRDye800CW-nimotuzumab for use as a near infrared imaging probe for image-guided surgery during lung cancer resection. IRDye800CW-nimotuzumab targets cancer cells over-expressing EGFR, allowing tumors to be visualized and may help surgeons better identify cancer during surgery.

NCT ID: NCT04455984 Recruiting - Clinical trials for Advanced Non-small-cell Lung Cancer

Multimodality Treatment Including Curative Resection of Advanced NSCLC

Start date: May 1, 2017
Phase:
Study type: Observational

This study retrospectively evaluates clinical parameters and outcome of patients with advanced stage non-small cell lung cancer treated with neoadjuvant therapy followed by curative-intent surgery at the Divison of Thoracic Surgery at the Medical University of Vienna

NCT ID: NCT04448379 Recruiting - Clinical trials for Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

Start date: June 29, 2020
Phase: Phase 1
Study type: Interventional

This study is a Phase Ib, open label, multi-center study of to evaluate the safety and efficacy of JMT101 combined with EGFR-TKIs (Afatinib or Osimertinib) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations.

NCT ID: NCT04447482 Recruiting - Lung Neoplasms Clinical Trials

ENB Vs. Conventional Bronchoscopy With Fluoroscopy for Safe and Effective Biopsy of Pulmonary Lesions

Start date: July 10, 2020
Phase: N/A
Study type: Interventional

Evaluate results for participants with lung lesions randomized to either 4D Electromagnetic Navigation Bronchoscopy (4D-ENB) versus Conventional Bronchoscopy with Fluoroscopy for diagnostic biopsy and detection of lung cancer.

NCT ID: NCT04441138 Recruiting - Clinical trials for Stage III Non-small-cell Lung Cancer

Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC

ESR1814205
Start date: February 25, 2021
Phase: Phase 2
Study type: Interventional

Elderly (age 70 years or older) or >18 years old AND poor risk (ECOG 2) newly diagnosed stage IIIA-C (AJCC 8th edition) inoperable non-small cell lung cancer (NSCLC) patients are eligible to participate in this phase II open label study of concurrent, split course chemoradiation followed by Durvalumab (MEDI4736).

NCT ID: NCT04439890 Recruiting - Clinical trials for Advanced Non-squamous Cell Non-small Cell Lung Cancer

A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer

Start date: August 8, 2019
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, multicenter phase III clinical study to evaluate efficacy and safety of anlotinib hydrochloride capsule combined with chemotherapy versus placebo combined with chemotherapy as first-line treatment in subjects with advanced non-squamous cell non-small cell lung cancer.

NCT ID: NCT04434482 Recruiting - Clinical trials for Small Cell Lung Cancer

IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer

Start date: August 7, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, multi-center, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, PK characteristics and anti-tumor activity of PARP inhibitor IMP4297 and temozolomide combination therapy in patients with advanced solid tumors and with ES-SCLC who develops disease progression after 1L platinum-based regimen.